Zovegalisib

Overview

Zovegalisib (RLY-2608) is an orally active first-in-class allosteric mutant-selective inhibitor of PI3Ka with anti-tumor activity. Zovegalisib inhibits tumor growth in PIK3CA-mutant xenograft mice models with minimal impact on insulin .

Application

Products | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > PI3K

Product Information

• Catalog No.: HY-153306
• CAS No.: 2733573-94-7
• Molecular Formula: C29H14ClF5N6O2
• Molecular Weight: 608.91
• Purity: 98.80%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 5 mg/mL (8.21 mM); Clear solution
• Availability: In-stock

Source

Original product source